{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rivastigmine+transdermal+patch",
    "query": {
      "intervention": "rivastigmine transdermal patch"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rivastigmine+transdermal+patch&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T23:27:56.263Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00948766",
      "title": "Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Rivastigmine 4.6 mg/24 h (5 cm^2)",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 9.5 mg/24 h (10 cm^2)",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 13.3 mg/24 h (15 cm^2)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 716,
      "start_date": "2009-07",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2013-08-28",
      "last_synced_at": "2026-09-07T23:27:56.263Z",
      "location_count": 93,
      "location_summary": "Tempe, Arizona • Tucson, Arizona • Conway, Arkansas + 84 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Conway",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00948766"
    },
    {
      "nct_id": "NCT03915626",
      "title": "Effect of Heat on Rivastigmine TDS Products",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Bioavailability"
      ],
      "interventions": [
        {
          "name": "Rivastigmine (RLD) transdermal patch",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine (generic) transdermal patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 7,
      "start_date": "2019-10-04",
      "completion_date": "2021-05-04",
      "has_results": true,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-09-07T23:27:56.263Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03915626"
    },
    {
      "nct_id": "NCT01602198",
      "title": "Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mild Cognitive Disorder",
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Exelon [rivastigmine] transdermal patch",
          "type": "DRUG"
        },
        {
          "name": "Placebo transdermal patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 1,
      "start_date": "2011-06",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2017-02-28",
      "last_synced_at": "2026-09-07T23:27:56.263Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01602198"
    },
    {
      "nct_id": "NCT03840837",
      "title": "Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson Disease",
        "Parkinson Disease Dementia"
      ],
      "interventions": [
        {
          "name": "Rivastigmine transdermal patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2019-05-02",
      "completion_date": "2020-04-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-20",
      "last_synced_at": "2026-09-07T23:27:56.263Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03840837"
    },
    {
      "nct_id": "NCT00506415",
      "title": "Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Rivastigmine 5 cm^2",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 10 cm^2",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 15 cm^2",
          "type": "DRUG"
        },
        {
          "name": "Placebo to 15 cm^2 patch",
          "type": "DRUG"
        },
        {
          "name": "Placebo to 10 cm^2 patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 1584,
      "start_date": "2007-06",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2012-09-19",
      "last_synced_at": "2026-09-07T23:27:56.263Z",
      "location_count": 65,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 61 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00506415"
    },
    {
      "nct_id": "NCT00623103",
      "title": "Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease Dementia"
      ],
      "interventions": [
        {
          "name": "Rivastigmine capsule",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine transdermal patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 583,
      "start_date": "2008-01",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2011-11-28",
      "last_synced_at": "2026-09-07T23:27:56.263Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Reseda, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Reseda",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00623103"
    },
    {
      "nct_id": "NCT01670526",
      "title": "Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Traumatic Brain Injury",
        "Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Rivastigmine Transdermal Patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 94,
      "start_date": "2012-12",
      "completion_date": "2017-09",
      "has_results": true,
      "last_update_posted_date": "2018-02-27",
      "last_synced_at": "2026-09-07T23:27:56.263Z",
      "location_count": 8,
      "location_summary": "San Diego, California • Miami, Florida • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Hines",
          "state": "Illinois"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01670526"
    },
    {
      "nct_id": "NCT01519271",
      "title": "Mild Cognitive Impairment in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson's Disease",
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Exelon Patch (rivastigmine transdermal system)",
          "type": "DRUG"
        },
        {
          "name": "Placebo Patches",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 28,
      "start_date": "2011-12",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2017-04-07",
      "last_synced_at": "2026-09-07T23:27:56.263Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01519271"
    },
    {
      "nct_id": "NCT00428389",
      "title": "Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Rivastigmine 5 cm^2 transdermal patch",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 10 cm^2 transdermal patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 262,
      "start_date": "2007-01",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2014-06-11",
      "last_synced_at": "2026-09-07T23:27:56.263Z",
      "location_count": 23,
      "location_summary": "Sun City, Arizona • Costa Mesa, California • Fresno, California + 20 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00428389"
    },
    {
      "nct_id": "NCT04732182",
      "title": "Telerehabilitation Alzheimer's Disease Feasibility (TADF)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Healthy Aging"
      ],
      "interventions": [
        {
          "name": "BrightGo cognitive training",
          "type": "DEVICE"
        },
        {
          "name": "Standard of Care medication for early Alzheimer's Disease",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Bright Cloud International Corp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "65 Years to 85 Years"
      },
      "enrollment_count": 14,
      "start_date": "2022-02-16",
      "completion_date": "2023-02-28",
      "has_results": false,
      "last_update_posted_date": "2022-05-02",
      "last_synced_at": "2026-09-07T23:27:56.263Z",
      "location_count": 2,
      "location_summary": "New Brunswick, New Jersey • North Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "North Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04732182"
    }
  ]
}